IBB Outperforms XBI: Top 10 Mid-Cap Stocks
IBB and XBI Underperformed in the Week Ending August 7
IBB outperforms XBI
Considering the market cap, the top ten mid-cap stocks from the iShares Nasdaq Biotechnology ETF (IBB) outperformed the top ten mid-cap stocks from the SPDR S&P Biotechnology ETF (XBI) for the week ending August 7, 2015.
The above graph reflects the performance of IBB’s top ten mid-cap stocks versus XBI’s top ten mid-cap stocks. IBB’s mid-cap stocks returned -5.92% and XBI’s mid-cap stocks returned -7.76% for the week ending August 7, 2015.
Alnylam, Opko Health, and Intrexon underperform
Alnylam Pharmaceuticals (ALNY) has a weight of 1.60% and 1.15% in IBB and XBI, respectively. The stock fell by 16.67% for the week ending August 7, 2015. Alnylam announced its 2Q15 results on August 6, 2015. According to the company’s press release, on a GAAP (generally accepted accounting principles) basis it reported a net loss of $71.8 million for 2Q15. In 2Q14, it reported a net loss of $44.1 million. This was a rise of ~62% on a YoY (year-over-year) basis.
Intrexon (XON) has a weight of 0.90% in XBI. The stock fell by 8.80% for the week ending August 7, 2015. The stock fell majorly because of profit booking by investors. However, the stock has risen ~75% YTD (year-to-date). On August 7, 2015, the trading volume was ~23% higher than the average volume. This probably indicates profit booking.
Opko Health (OPK) has a weight of 1.25% in XBI’s portfolio. The stock fell by 15.94% for the week ending August 7, 2015. The stock fell due to the widening loss reported for the second quarter. According to the company’s press release, Opko Health’s revenue for 2Q15 was $42.4 million—compared to $23.5 million for 2Q14. The revenue and the net loss both rose. The company reported a net loss of $42.8 million for 2Q15—compared to a net loss of $25.5 million for 2Q14.
Browse this series on Market Realist: